Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3632 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Biovail posts disappointing Q2 results

The company is now hoping to compensate for the disappointing results with the launch of its new drug pipeline which includes BVF-324, a sexual-dysfunction treatment, as well as

Abraxis BioScience launches generic Adriamycin

Abraxis’ doxorubicin injection is the generic equivalent of Adriamycin PFS which is owned by Bedford Laboratories, a division of Boehringer Ingelheim. According to IMS, sales in 2006 of

FDA rejects higher dose of GSK’s Advair

The FDA questioned how Advair 500/50 compared to the currently approved 250/50 strength in order to allow for appropriate dosing recommendations. GSK says it will be meeting with